{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-059117","form_type":"8-K","ticker":"BGMS","cik":"0001130166","company_name":"Bio Green Med Solution, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.018976+00:00","generated_at":"2026-06-15T03:34:02.374179+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cyclacel Q1 net loss $5.8M; non-dilutive $4.7M tax credit bolsters cash into Q1 2024","bullets":["Net loss $5.8M in Q1 2023 vs $4.1M year ago; cash $11.4M plus $4.7M R&D tax credit received.","R&D expenses $5.7M, up 14% YoY, with fadraciclib costs $4.1M and plogosertib $1.4M.","Expects Phase 1/2 data for oral fadraciclib and plogosertib in 2023; Phase 2 PoC enrollment ready.","Cash runway estimated into Q1 2024; royalty income declined $1.1M YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-059117","json":"https://secwatch.observer/filing/0001104659-23-059117.json","markdown":"https://secwatch.observer/filing/0001104659-23-059117.md","text":"https://secwatch.observer/filing/0001104659-23-059117.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923059117/0001104659-23-059117-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923059117/tm2315482d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T03:34:02.374179+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9c45f77a7b5fab616be0bb3f35ec01db4678ed16","claim":"Bio Green Med Solution, Inc. reported first quarter ended March 31, 2023 results: net income Net loss for the three months ended March 31, 2023, was $5.8 million.","evidence_excerpt":"Net loss for the three months ended March 31, 2023, was $5.8 million, compared to $4.1 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923059117/0001104659-23-059117-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss for the three months ended March 31, 2023, was $5.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}